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Spondyloenchondrodysplasia (SPENCD) is an autosomal recessive skeletal dysplasia 
caused by loss of function mutations in acid phosphatase 5, tartrate resistant (ACP5). 
Hypomorphic ACP5 mutations impair endochondral bone growth and create an inter-
feron (INF) signature, which lead to distinctive spondylar and metaphyseal dysplasias, 
and extraskeletal morbidity, such as neurological involvement and immune dysregula-
tion, respectively. We report an affected boy with novel ACP5 mutations, a splice-site 
mutation (736-2 A>C) and a nonsense mutation (R176X). He presented with postnatal 
short stature, which led to a diagnosis of partial growth hormone (GH) deficiency at 
3 years of age. GH therapy was beneficial in accelerating his growth velocity. At 6 years 
of age, however, metaphyseal abnormalities of the knee attracted medical attention, and 
subsequent assessment ascertained the typical skeletal phenotype of SPENCD, brain 
calcifications, and an INF signature. This anecdotal experience indicates the potential 
efficacy of GH for growth failure in SPENCD.
Keywords: spondyloenchondrodysplasia, aCp5, growth hormone deficiency, growth hormone therapy, skeletal 
dysplasia
INtRoDUCtIoN
Spondyloenchondrodysplasia (SPENCD, OMIM #607944) is a rare autosomal recessive skeletal dys-
plasia characterized by vertebral dysplasia and enchondroma-like radiolucent metaphyseal lesions 
of the long bones (1). Affected individuals manifest with short-trunked short stature. In addition, 
they show a variety of extraskeletal abnormalities, including neurological symptoms (intracranial 
calcification, developmental delay, spasticity, clumsy movements), and immune dysregulation (auto-
immune diseases, immunodeficiency) (2–10). Recently, two groups reported biallelic hypomorphic 
mutations in the Acid Phosphatase 5, Tartrate Resistant (ACP5) gene as a genetic cause of SPENCD 
(11, 12). ACP5 encodes tartrate-resistant acid phosphatase (TRAP). TRAP deficiency increases levels 
of phosphorylated osteopontin, which causes dysregulated endochondral ossification and other 
manifestations, and also an interferon (INF) signature (increased expression of type I INF regulated 
genes) leading to extraskeletal complications (11–13). Very little is documented concerning medical 
intervention for short stature and INF signature in SPENCD. Some SPENCD reports have mentioned 
attempts of growth hormone (GH) therapy, but the effect of GH has not been fully detailed (4, 10).
We report here an affected Japanese boy with novel compound heterozygous ACP5 mutations, 
who had the typical skeletal phenotype of SPENCD, brain calcifications, absence of TRAP activity, 
FIGURe 1 | (a) Family tree. (B) Growth curve. At age 38 months, the patient’s height was 84.5 cm (−2.89 SD) and growth hormone (GH) therapy was commenced. 
The patient’s growth curve significantly improved with GH treatment over time. Height curve; red circles, weight curve; blue squares.
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and laboratory findings of an INF signature, but no immuno-
deficiency or autoimmune disorders. He had developed short 
stature in early childhood, leading to a diagnosis of partial GH 
deficiency (GHD) and introduction of GH therapy prior to the 
definitive diagnosis of SPENCD. Interestingly, his growth velocity 
was significantly accelerated in response to GH treatment.
Case RepoRt
The patient is a 6-year-old Japanese boy who was born to non-
consanguineous healthy parents. The patient’s mid-parental 
target height was 180 cm (final height of his father and mother 
was 177 and 170 cm, respectively). His older brother was healthy 
(Figure 1A). He was born at term after an uncomplicated preg-
nancy and delivery. Birth weight was 3,055 g (−0.64 SD), length 
51.5 cm (+1.06 SD), and head circumference 34.0 cm (+0.40 SD). 
At 19 months, he was referred to us because of his inability to 
walk unaided. At that time brain MRI yielded a normal finding. 
He entered a rehabilitation program that improved his ambula-
tion. His linear growth started to slow down from 5  months 
of age. At 38 months of age his height was 84.5 cm (−2.89 SD) 
(Figure 1B). Thyroid function was normal (TSH 4.520 μU/mL, 
FT4 1.06 ng/dL). The level of baseline insulin-like growth factor 
I (IGF-I) was low (18 ng/mL). These clinical manifestations and 
results of a GH stimulation test led to the diagnosis of partial 
GHD (peak GH response to arginine was 4.60  ng/mL and to 
clonidine was 2.41  ng/mL; the cut-off point was <6  ng/mL 
to define partial GHD and <3  ng/mL to define severe GHD) 
(Table S1 in Supplementary Material). GH therapy (0.175 mg/
kg/week) was introduced, and it significantly accelerated his 
growth velocity (Figure 1B).
At 6 years of age, he presented with painful knee joints. Height 
was 109.5 cm (−1.04 SD), and arm span was 111 cm. Facial features 
and body proportion were normal (Figure  2A). Development 
(language and cognitive skills, and fine and gross motor skills) 
was appropriate for his age, other than some clumsiness in 
motion. A radiograph of the knee showed mild metaphyseal dys-
plasia of the knee (shaved contour and marginal spur in the distal 
femoral metaphyses and to a lesser extent in the proximal tibial 
metaphyses, and mild cupping proximal fibular metaphyses) 
(Figure 2C). A subsequent skeletal survey revealed generalized 
metaphyseal dysplasia involving the hip and wrist as well as the 
knee (Figures 2D,E). The spine showed generalized platyspon-
dyly with irregular endplates. The posterior vertebral bodies were 
irregularly ossified (Figure  2B). These radiographic findings 
raised a suspicion of SPENCD. Laboratory data showed normal 
levels of serum calcium, phosphate, alkaline phosphatase, intact 
PTH, IGF-I, and thyroid function (Table S1 in Supplementary 
Material). No immunological abnormality was found, including 
normal levels of complements and no detectable autoantibodies. 
TRAP activity was undetectable (TRAP-5b <  0.1  U/L). Bone 
mineral density on dual-energy x-ray absorptiometry was normal 
(L1–L4: 0.942 g/cm2). Brain CT of the patient showed bilateral 
calcifications of the basal ganglia (Figure 2F).
FIGURe 2 | (a) Clinical photographs. (B) Spinal radiograph showing generalized platyspondyly with irregular endplates and irregular ossifications in the posterior 
vertebral bodies. (C) Radiograph of the knees showing irregular and sclerotic splayed metaphyses of the distal femur, proximal tibia, and fibula. (D,e) Radiograph of 
the hip and wrist showing similar metaphyseal changes as the knee. (F) Brain CT showing bilateral calcification of the basal ganglia.
FIGURe 3 | (a,B) Chromatograms showing the novel heterozygous mutations in ACP5 identified in the patient; a splice-site mutation (c.736-2 A>C) (a) and a 
nonsense mutation (c.526 C>T; p.R176X) (B). (C) Quantitative RT-PCR of INF-stimulated gene expression for, IFI27, IFIT1, IFI44L, ISG15, RSAD2, SIGLEC1 in 
peripheral blood cells. The relative abundance of each transcript was normalized to the expression of β-actin. The experiment was performed in triplicate. Healthy 
control (n = 8); black circles, patient; red circles.
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MateRIaLs aND MetHoDs
Genetic analysis
The genetic study of the patient was performed using a candi-
date gene approach with Sanger sequencing of the ACP5 gene. 
A familial study was not performed because consent was not given.
INF analysis
The expression of INF-stimulated genes in the patient’s whole 
blood cells were measured by qPCR as described previously (14). 
Whole blood was collected into PAXgene tubes (PreAnalytix, 
Hombrechtikon, Swizerland) and frozen at −20°C until extrac-
tion using the manufacturer’s protocol. Total RNA was extracted 
taBLe 1 | Literature review of SPENCD case reports.






Schorr et al. Pt. 1 M 8 years Short stature Yes No ND No (1)
Pt. 2 M 5 years Short stature Yes No ND Recurrent infections
Gustavson 
et al.
Pt. 3 F 15 months Short stature −7.5 SD at 16 yearsa No ND ND (15)
Pt. 4 M Birth Short stature, short limbs, bowlegs −6.5 SD at 13 yearsa No ND ND
Sauvegrain 
et al.
Pt. 5 F 16 years Short stature, short neck Yes No ND ND (16)
Pt. 6 M 7 years Short stature, Dev. delay Yes Dev. delay ND ND
Chagnon et al. Pt. 7 M 8 years Spastic quadriplegia Yes Spasticity ND ND (17)
Menger et al. Pt. 8 M Birth Short limbs −6 SD at 12 years Dev. delay ND ND (18)
Pt. 9 M Birth Short limbs −6 SD at 9 years Dev. delay ND ND
Pt. 10 M 4 months Craniotabes, costochondral beading −1.5 SD at 12 years No ND ND
Pt. 11 M 6 years Short stature, spastic quadriplegia, 
kyphoscoliosis
−2 SD at 6 years Dev. delay and 
spasticity
ND ND
Frydman et al. Pt. 12 M 2.5 years Short stature −2.5 SD at 11 years No No No (2)
Pt. 13 F 2 years Short stature −3.5 SD at 8 years No No ND
Pt. 14 M 10 years ND ND ND ND ND
Pt. 15 M 15 years Short stature, kyphosis, pectus carinatum, 
spastic quadriparesis
−3 SD at 15 years Spasticity Yes ND
Pt. 16 M 2 years Walking difficulties, spastic quadriparesis −4.4 SD at 8 years Dev. delay and 
spasticity
Yes ND
Pt. 17 M 18 years Lack of ejaculate −5.4 SD at 18 years No Yes ND
Robinson 
et al.
Pt. 18 M 11 years Short stature, joint pain <3rd percentile at 19 years No ND ND (19)
Pt. 19 M ND ND −5.5 SD at 86 yearsa ND ND ND
Uhlmann et al. Pt. 20 M Birth Short stature, clubfoot, diastasis recti, low-
set ears, simian creases, short neck
<3rd percentile at 5 years No ND No (20)
Pt. 21 M 11 months Short stature Yes No ND No
Roifman and 
Melamed
Pt. 22 F 5 months Recurrent infections <3rd percentile at 18 years No ND Recurrent infections, ITP, 
hypothyroidism, vitiligo
(3)
Pt. 23 M 3 months Recurrent infections ND No No Recurrent infections, ITP, 
hypothyroidism
Pt. 24 M 3 years Recurrent infections Yes No ND Recurrent infections, ITP
Pt. 25 M Infancy Recurrent infections Around 10th percentile at 
10 years
No ND Recurrent infections, JRA, 
Crohn’s disease, hypothyroidism, 
vitiligo
Tuysuz et al. Pt. 26 M 10 years Short stature <3rd percentile at 10 years No No ND (4)
Pt. 27 F 9 years Short stature <3rd–10th percentile at 21 years No No ND
Pt. 28 M 7 years Short stature, Dev. delay <3rd percentile at 7 years Dev. delay Yes ND
Bhargava 
et al.
Pt. 29 M 7 years Back pain, kyphosis <5th percentile at 13 years No ND No (21)
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Renella et al. Pt. 31 M 3 years Short stature <3rd percentile at 3 years No No SLE (5)
Pt. 32 F 8 months Leg stiffness <3rd percentile at 3 years Dev. delay and 
spasticity
Yes No
Pt. 33 F 1 months Short stature Yes No ND No
Pt. 34 M 1 months Leg stiffness <3rd percentile at 18 years Dev. delay and 
spasticity
Yes AIHA, FUO, ITP
Pt. 35 M 21 months Leg stiffness, spastic paraparesis Yes Dev. delay and 
spasticity
ND ITP, AIHA
Pt. 36 M 10 years Recurrent thrombocytopenia,  
recurrent fever of unknown origin
<3rd percentile at 17 years Dev. delay and 
spasticity
Yes ITP, FUO
Pt. 37 M Childhood Short stature Yes Spasticity ND ND
Pt. 38 F 11 years Rheumatic fever with carditis,  
sydenham chorea
<3rd percentile at 12 years No ND Rheumatic fever
Pt. 39 M 8 months Short stature <3rd percentile at 7 years Dev. delay and 
spasticity
No Inflammatory syndrome with 
hypogammaglobulinemia, AIHA
Kulkarni et al. Pt. 40 M 2 years Recurrent infections <5th percentile at 5 years No ND Recurrent infections, 
compromised cellular immunity, 
SLE, ITP, JRA
(6)





Pt. 42 M 2.5 years Walking difficulties, skin rash <5th percentile at 10 years Spasticity Yes Leukocytoclastic vasculitis, SLE
Girschick et al. Pt. 43 F 6 months Increased muscle tone of the  
lower limbs
Yes Spasticity No AIHA, ITP, polyarthritis, hepatitis, 
nephritis, life-threatening 
hyperreactivity to viral infections 
as well as recurrent bacterial 
infections
(8)
de Bruin et al. Pt. 44 F 13 years Short stature −5.5 SD at 13 years Dev. delay No No (22)
Pt. 45 M 8 years Short stature −5.1 SD at 8 years Dev. delay No No
Bilginer et al. Pt. 46 M 5 years Short stature <3rd percentile at 5 years ND Yes SLE (lupus nephritis) (9)
Pt. 47 F 16 years Short stature, arthralgia, arthritis <3rd percentile at 16 years ND Yes SLE (lupus nephritis), vitiligo
Pt. 48 F 4.5 years Leg stiffness, walking difficulties <3rd percentile at 16 years Spasticity Yes SLE (lupus nephritis)
M, male; F, female; ND, not described; Dev. delay, developmental delay; ITP, idiopathic thrombocytopenic purpura; JRA, juvenile rheumatoid arthritis; SLE, systemic lupus erythematosus; AIHA, autoimmune hemolytic anemia; FUO, 
fever of unknown origin.
aDescribed in Ref. (10).
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with a PAXgene RNA Blood kit (PreAnalytix) and reverse-
transcribed to cDNA using an Omniscript RT kit (Qiagen, 
Hilden, Germany). Real time quantitative PCR was performed in 
triplicate using a 7900HT Fast Real-Time PCR system (Applied 
Biosystems, Waltham, MA, USA) and a kit for each INF-
stimulated gene (IFI27, Hs01086370_m1; IFIT1, Hs00356631_
g1; RSAD2, Hs01057264_m1; SIGLEC1, Hs00988063_m1; 
ISG15, Hs00192713_m1; IFI44L, Hs00199115_m1; BACT, 
Hs01060665_g1) (Life Technologies, Carlsbad, CA, USA). The 
expression levels were normalized to those of β-actin. Results 
are shown relative to a single calibrator (control 1).
ResULts
Identification of ACP5 Mutations
The sequence analysis revealed novel ACP5 mutations, a splice-
site mutation (c.736-2 A>C) and a nonsense mutation (c.526 
C>T; p.R176X) (Figures 3A,B). Neither 736-2 A>C nor R176X 
were found in the NCBI, Ensembl, dbSNP, or ExAc databases.
Detection of INF signature
We identified marked upregulation of IFI27, IFIT1, IFI44L, 
ISG15, RSAD2, and SIGLEC1 in the patient compared with 
healthy controls (n = 8) (Figure 3C).
DIsCUssIoN
We report a boy with a typical SPENCD skeletal phenotype, who 
presented with postnatal short stature and brain calcifications. 
He has not developed immune dysregulation despite laboratory 
evidence of a type I INF signature. An IFN signature in SPENCD 
plays a major role in neurological and immune involvement. 
We summarized the clinical manifestations of 48 patients with 
SPENCD by reviewing previous reports, as presented in Table 1 
(1–9, 15–22). Height ranged from −1.5 to −7.5 SD (only cases 
with SD notation were included). The common features that first 
prompt the seeking of medical attention include musculoskeletal 
symptoms (60.4%), such as short stature, short limbs, kyphosco-
liosis, and bowlegs, followed by neurological symptoms (27.1%) 
and immune dysregulation (18.8%). On the other hand, Briggs 
et al. (10) reviewed 26 patients, including 12 previously reported 
patients, and identified that up to 50% initially presented with 
immune dysregulation, followed by musculoskeletal symptoms 
(46.2%) and neurological symptoms (23.1%). This difference 
between our review and Briggs’ may represent the clinical diver-
sity of SPENCD.
In the present case, postnatal growth failure was ameliorated 
with GH therapy; height increased from −2.89 SD to −1.04 
SD over 3  years. The patient’s IGF-I levels increased to within 
the normal range after commencing GH therapy (Figure S1 in 
Supplementary Material). In addition, GH therapy did not accel-
erate bone age; bone ages were 2.3 and 5.2 years at the chronologi-
cal ages of 3 years 4 months and 6 years 11 months, respectively. 
These findings indicate the potential therapeutic benefit of GH to 
improve short stature in patients with SPENCD.
Two reports have been published describing three SPENCD 
patients who underwent GH therapy (4, 10). Briggs et  al. (10) 
described two patients, including one patient with GHD who 
responded well to GH therapy. Tuysuz et  al. (4) reported a 
21-year-old woman with SPENCD who received GH therapy for 
2 years from the age of 9 years such that she achieved a normal 
height (153 cm: 3–10 centile). It remains unclear whether a good 
response to GH therapy in these SPENCD patients is universal 
or not. Lack of TRAP leads to an increase in phosphorylated 
osteopontin, which is responsible for disordered endochondral 
ossification and reduced resorption of calcified cartilage matrix 
and primary spongiosa as a result of impaired adhesion, migra-
tion, and activation of osteoclasts (11, 13, 23, 24). Meanwhile, GH 
advances longitudinal bone growth directly by stimulating pre-
chondrocyte differentiation, and indirectly by clonal expansion 
of differentiated chondrocytes through upregulation of IGF-I 
(25–29). Moreover, GH stimulates resorption of cartilage matrix 
and immature bone through both its direct and indirect actions 
on osteoclast formation and differentiation and through indirect 
activation of mature osteoclasts via osteoblasts. Upregulation 
of IGF-I associated with GH therapy also supports osteoclastic 
activities (30, 31). These effects of GH may efficiently counteract 
the negative effects on endochondral bone growth in SPENCD.
Growth hormone therapy is associated with adverse risks 
in some patients, such as femoral head necrosis, slipped 
capital femoral epiphysis, exostosis, and the progression of bone 
deformities, particularly spinal deformities, such as scoliosis. 
We have not observed any obvious adverse events associated 
with GH therapy in the present case up to this time. However, 
because only 3 years has passed since the patient commenced GH 
therapy, the patient will require regular follow-up to evaluate the 
potential long-term effects of GH therapy. In addition, there are 
some other limitations in our study. First, the patient has partial 
GHD as well as SPENCD, and therefore the potential benefit of 
GH therapy for short stature in patients with SPENCD might be 
overestimated. Second, the patient is 6 years old and is too young 
to evaluate the effect of GH therapy on his final height. Despite 
these limitations, however, the improvement in growth velocity 
found in the present case is encouraging and may suggest the 
potential therapeutic benefit of GH in patients with SPENCD.
CoNCLUDING ReMaRKs
This case report described the treatment of a patient who pre-
sented progressive growth failure associated with SPENCD and 
partial GHD. After commencing GH therapy, the patient’s height 
SD score improved from −2.89 SD to −1.04 SD over 3 years with-
out accelerating the bone age. Considering the improvement in 
growth velocity in the present case, it is reasonable to suggest that 
GH therapy is warranted in patients with SPENCD, at least for 
those who show evidence of a partial GHD. Further studies are 
recommended to evaluate the benefit of GH therapy in improving 
the height of patients with SPENCD, even in the absence of GHD.
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